+48.3%
LLY vs MRNA
+909.7%
-861.3%
-23.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.8% | -6.5% | +2.8% | -3.5% |
| 7D | -0.7% | +8.4% | -9.0% | -1.0% |
| 30D | +17.9% | +28.8% | -10.9% | +16.7% |
| 3M | +16.8% | +329.2% | -312.4% | +7.6% |
| 6M | +38.4% | +416.9% | -378.5% | +24.1% |
| YTD | +27.6% | +718.8% | -691.2% | +10.6% |
| 1Y | +48.3% | +924.9% | -876.5% | +26.1% |
| All | +48.3% | +909.7% | -861.3% | +26.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling